$30.99
1.11%
Nasdaq, Aug 29, 10:00 pm CET
ISIN
US22663K1079
Symbol
CRNX

Crinetics Pharmaceuticals Inc Stock price

$30.99
+1.72 5.88% 1M
-4.79 13.39% 6M
-20.14 39.39% YTD
-21.71 41.20% 1Y
+11.20 56.59% 3Y
+14.96 93.33% 5Y
+6.48 26.44% 10Y
+6.48 26.44% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.34 1.11%
ISIN
US22663K1079
Symbol
CRNX
Industry

Key metrics

Basic
Market capitalization
$2.9b
Enterprise Value
$1.7b
Net debt
positive
Cash
$1.2b
Shares outstanding
94.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2,099.7 | 476.5
EV/Sales
1,239.0 | 281.2
EV/FCF
negative
P/B
2.5
Financial Health
Equity Ratio
92.4%
Return on Equity
-22.5%
ROCE
-34.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.4m | $6.1m
EBITDA
$-419.6m | $-451.2m
EBIT
$-423.1m | $-480.2m
Net Income
$-369.8m | $-456.6m
Free Cash Flow
$-307.8m
Growth (TTM | estimate)
Revenue
0.0% | 488.9%
EBITDA
-51.9% | -34.3%
EBIT
-52.2% | -41.7%
Net Income
-43.0% | -53.0%
Free Cash Flow
-66.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-30,144.9% | -7,366.9%
EBIT
-30,392.2%
Net
-26,568.5% | -7,455.2%
Free Cash Flow
-22,111.9%
More
EPS
$-3.9
FCF per Share
$-3.3
Short interest
16.8%
Employees
437
Rev per Employee
$0.0
Show more

Is Crinetics Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Crinetics Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:

21x Buy
88%
3x Hold
13%

Analyst Opinions

24 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:

Buy
88%
Hold
13%

Financial data from Crinetics Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1.39 1.39
0% 0%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 139 139
78% 78%
10,032%
- Research and Development Expense 285 285
42% 42%
20,504%
-420 -420
52% 52%
-30,188%
- Depreciation and Amortization 3.44 3.44
94% 94%
247%
EBIT (Operating Income) EBIT -423 -423
52% 52%
-30,436%
Net Profit -370 -370
43% 43%
-26,606%

In millions USD.

Don't miss a Thing! We will send you all news about Crinetics Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Crinetics Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
12 days ago
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH). Atumelnant is the fi...
Neutral
GlobeNewsWire
21 days ago
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an aggregate of 53,400 restricted stock unit (“RSU”) awards to 27 new non-executive employees, ...
Neutral
Seeking Alpha
24 days ago
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alan S. Krasner - Corporate Participant Chief Endocrinologist - Corporate Participant Dana Pizzuti - Chief Medical & Development Officer Gayathri Diwakar - Head of Investor Relations Isabel Kalofonos - Chief Commercial Officer R.
More Crinetics Pharmaceuticals Inc News

Company Profile

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Scott Struthers
Employees 437
Founded 2008
Website www.crinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today